Drug Trial Radar · NCT07557498
Mavacamten Outcomes in Hypertrophic Cardiomyopathy (HCM) and the Associated Patient and Physician Experiences in the US
Last checked: Nov 20, 2026Latest source record: Apr 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
362
Planned (sponsor's estimate)
Start
Jan 15, 2026
Primary completion
Dec 14, 2026
Study completion Jun 17, 2027
Sponsor
- Lead sponsor
- Bristol-Myers SquibbBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- First posted
- Apr 29, 2026
Design
- Study type
- Observational
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to understand the real-world clinical outcomes and treatment patterns of adults with obstructive hypertrophic cardiomyopathy (HCM) treated with mavacamten, and to understand patient and physician experiences with mavacamten treatment, in the US community-based practice
Conditions
- Obstructive Hypertrophic Cardiomyopathy (oHCM)
Interventions
MavacamtenDrug
According to the product label
Primary outcomes
What the sponsor says the trial is designed to measure.
- Participant blood pressure (both systolic and diastolic)Time frame: Baseline
- Date of diagnosis of hypertrophic cardiomyopathyTime frame: Baseline
- Hypertrophic cardiomyopathy genetic testing resultsTime frame: Baseline
- Family history of hypertrophic cardiomyopathyTime frame: Baseline
- Family history of Sudden Cardiac Death (SCD)Time frame: Baseline
- Participant comorbidities (cardiovascular and non-cardiovascular )Time frame: Baseline
- Type of prior surgeries and proceduresTime frame: Baseline and up to week 24
- Participant New York Heart Association (NYHA) class categoryTime frame: Baseline, and at weeks 4, 8, 12, 24
- Change in participant New York Heart Association (NYHA) class from baselineTime frame: Baseline, and at weeks 4, 8, 12, 24
- Duration of mavacamten treatmentTime frame: Baseline, and at weeks 4, 8, 12, 24
- Number of mavacamten dose titrationsTime frame: Baseline, and at weeks 4, 8, 12, 24
- Type of mavacamten dose tritrationTime frame: Baseline, and at weeks 4, 8, 12, 24
- Clinical reason for mavacamten dose titrationTime frame: Baseline, and at weeks 4, 8, 12, 24
- Clinical reason for mavacamten treatment discontinuationTime frame: Baseline, and at weeks 4, 8, 12, 24
- Left Ventricular Ejection Fraction (LVEF) recovery after mavacamten discontinuation if discontinued due to LVEF<50%,Time frame: Baseline, and at weeks 4, 8, 12, 24
- Time from mavacamten discontinuation to Left Ventricular Ejection Fraction (LVEF) recoveryTime frame: Baseline, and at weeks 4, 8, 12, 24
- Clinical reason for temporary mavacamten treatment interuptionTime frame: Baseline, and at weeks 4, 8, 12, 24
- Time to temporary mavacamten treatment interruptionTime frame: Baseline, and at weeks 4, 8, 12, 24
- Left Ventricular Ejection Fraction (LVEF) recovery after mavacamten interruption if the interruption was due to LVEF<50%Time frame: Baseline, and at weeks 4, 8, 12, 24
- Time from mavacamten treatment interruption to Left Ventricular Ejection Fraction (LVEF) recoveryTime frame: Baseline, and at weeks 4, 8, 12, 24
- Time to mavacamten treatment resumptionTime frame: Baseline, and at weeks 4, 8, 12, 24
- Type of hypertrophic cardiomyopathy (HCM) background therapy prescribedTime frame: Baseline, and at weeks 4, 8, 12, 24
- Type of changes to hypertrophic cardiomyopathy (HCM) background therapyTime frame: At baseline, weeks 4, 8, 12, 24
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Adelphi Real World
Bollington, Macclesfield, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.